Unexpected cross-reactivity in a cat-allergy patient. An allergic reaction at the circus.

1. Brahimi N, Routier E, Raison-Peyron, Tronquoy AF, PougetJasson, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20:461--4. 2. Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol. 2000;1:277--85. 3. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9: 316--21. 4. Andrade P, Brinca A, Gonçalo M. Patch testing in fixed drug eruptions -a 20-year review. Contact Dermatitis. 2011;65: 195--201. 5. Andrade P, Gonçalo M. Fixed drug eruption caused by etoricoxib -2 cases confirmed by patch testing. Contact Dermatitis. 2011;64:110--20. 6. Calistru AM, Cunha AP, Nogueira A, Azevedo F. Etoricoxibinduced fixed drug eruption with positive lesional patch test. Cutan Ocul Toxicol. 2011;30:154--6. 7. Augustine M, Sharma P, Stephen J, Jayaseelan E. Fixed drug eruption and generalised erythema following etoricoxib. Indian J Dermatol Venereol Leprol. 2006;72:307--9. 8. Duarte AF, Correia O, Azevedo R, PalmaresM D, Delgado L. Bullous fixed drug eruption to etoricoxib -further evidence of intraepidermal CD8+ T cell involvement. Eur J Dermatol. 2010;20:236--8. 9. Marina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39:854--62. 10. Ponce V, Muñoz-Bellido F, Moreno E, Laffond E, González A, Dávila I. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib. Contact Dermatitis. 2012;66:107--8.